Merck Commercial Model: Expand Customer Base, Tighten Marketing Spend
Executive Summary
Merck expects to reduce its marketing spend by about 15 to 20 percent per product, Global Pharmaceuticals President Adam Schechter told the Pharmaceutical Strategic Alliances conference in New York on September 25
You may also be interested in...
Merck Names Ken Frazier President
The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.
Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA
FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain
Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA
FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain